Skip to main content
. Author manuscript; available in PMC: 2021 Mar 22.
Published in final edited form as: Chem Biol Drug Des. 2017 Nov 3;91(2):491–504. doi: 10.1111/cbdd.13110

SCHEME 1.

SCHEME 1

Workflow that resulted in the trial compounds that were experimentally verified in Xiao et al. along with the refinements that lead to the hypothesis that the antagonist molecules are disrupting protein–protein interactions between FGF23 and FGFR